Epitalon, also called Epithalon or AEDG, is a synthetic tetrapeptide studied mainly in Russian gerontology literature. PubMed-indexed human trials exist, including randomized studies, but the evidence base is narrow and does not prove broad anti-aging or lifespan benefits for healthy adults. Chia does not offer Epitalon.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
Epitalon is a short synthetic peptide, commonly described as the tetrapeptide AEDG. It is also called Epithalon, while Epithalamin or epithalamine appears in older studies of pineal peptide preparations 5.
Names and synonyms
- Epitalon: the spelling used in a PubMed-indexed clinical trial of retinitis pigmentosa 2.
- Epithalon: a common alternate spelling used in patient searches and longevity forums.
- Epithalamin or epithalamine: older terms used in PubMed-indexed studies of pineal gland peptide preparations 5, 7.
- AEDG: the four-amino-acid shorthand often used in mechanistic discussions of this peptide class 10.
Peptide class and one-line definition
Epitalon is best understood as a 4-amino-acid synthetic peptide studied in the broader family of pineal and bioregulatory peptides. The supplied records include human studies, but they do not establish Epitalon as a general anti-aging treatment for healthy adults 1, 7.
What this page can and cannot answer
This page can summarize the PubMed-indexed human studies supplied for Epitalon and related pineal peptide preparations. It cannot tell you whether Epitalon is right for you, and it cannot provide a self-use dosing plan.
If you are comparing longevity peptides more broadly, our guides to what Epitalon peptide does, Epitalon evidence and safety, and the Epitalon telomere hypothesis go deeper on related patient questions.
Mechanism of action
Epitalon’s mechanism in humans is not fully established. The main proposed pathways are pineal signaling, circadian melatonin rhythm, telomerase-related biology, and cell-differentiation signaling, but these mechanisms should not be treated as proven clinical outcomes.
Pineal peptide and circadian-melatonin hypotheses
Older human research studied epithalamin, a pineal peptide preparation, in relation to the circadian rhythm of melatonin-producing function in elderly people 5. That supports a circadian-melatonin research hypothesis, not a claim that Epitalon reliably improves sleep, aging, or hormone balance in healthy adults.
Telomerase and cell-differentiation hypotheses
Reviews and laboratory-focused papers discuss short peptides, including pineal peptide concepts, in relation to cell differentiation and aging biology 10, 12. These are mechanistic ideas. They do not prove that Epitalon lengthens human lifespan, changes appearance, or improves healthspan.
A 2025 review describes Epitalon as a highly bioactive pineal tetrapeptide with promising properties, but a review is not the same as a new randomized trial in patients 12. For longevity claims, human outcomes matter more than cell or biomarker signals.
Why mechanism evidence is not the same as benefit
A pathway can be biologically interesting and still fail to create a clear patient benefit. That is why we separate mechanism, human evidence, dosing evidence, and safety instead of treating them as one story.
Evidence
Epitalon has Grade A evidence by the supplied quantity-and-design rubric, because the retrieved PubMed records include at least two human randomized controlled trials. That grade does not mean Epitalon has proven broad anti-aging benefit or proven safety.
How to interpret Grade A
Grade A is a count-and-design grade. It tells us that human randomized controlled trials exist, including studies in elderly people described as having rapid or accelerated aging and studies of related pineal peptide preparations 1, 7.
It does not tell us that the trials were large, modern, independently replicated, or designed for healthy adults seeking longevity support. The supplied records include older studies and specialized patient groups, so the findings need cautious interpretation 3, 5.
Where the evidence is strongest
The strongest supplied evidence is that Epitalon or related pineal peptide preparations have been studied in humans. PubMed-indexed records include randomized studies in elderly people with rapid or accelerated aging 1, 7, a randomized study of melatonin-producing rhythm in elderly people 5, and a randomized study of diurnal arterial-pressure profile in women with ischemic heart disease and arterial hypertension 3.
The supplied literature also includes a clinical trial in retinitis pigmentosa 2, a clinical trial in combined craniocerebral trauma 6, and older studies in cervical cancer contexts 8, 9. These study areas are not interchangeable, and they should not be converted into general wellness claims.
Where the evidence is still thin
The evidence is thin for common consumer questions like “Will Epitalon make me look younger?”, “Will it help me lose weight?”, or “Will it extend my lifespan if I am healthy?” The supplied human records do not establish those outcomes for healthy adults.
The supplied registry snapshot lists no registered trials for this page. That matters because registered trials make it easier to see planned outcomes, methods, and safety monitoring before results are published.
| Evidence area | Human evidence in supplied records | What it can support | What it cannot prove |
|---|---|---|---|
| Accelerated or rapid aging | Randomized controlled trial records and long-term follow-up records exist 1, 7 | Epitalon-related preparations were studied in elderly people described in these records | Broad anti-aging benefit for healthy adults |
| Circadian melatonin rhythm | Randomized controlled trial record in elderly people 5 | A melatonin-rhythm hypothesis was studied | Reliable sleep improvement or hormone optimization |
| Cardiovascular profile | Randomized controlled trial record in women with ischemic heart disease and arterial hypertension 3 | Diurnal arterial-pressure profile was studied | Blood-pressure treatment claims |
| Retinitis pigmentosa | Clinical trial record 2 | Retina condition was studied in that disease context | Vision benefit for people without that condition |
| Cancer contexts | Older clinical and randomized records in cervical cancer contexts 8, 9 | Historical research existed | Cancer treatment, prevention, or survival claims |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2011 | Randomised controlled trial | Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up | Bulletin of experimental biology and medicine | PMID 22451889 |
| 2002 | Clinical trial | Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa | Neuro endocrinology letters | PMID 12195242 |
| 2008 | Randomised controlled trial | [Effect of the pineal gland peptide preparation on the diurnal profile of arterial pressure in middle-aged and elderly women with ischemic heart disease and arterial hypertension] | Advances in gerontology = Uspekhi gerontologii | PMID 18546838 |
| 2003 | Randomised controlled trial | Peptides of pineal gland and thymus prolong human life | Neuro endocrinology letters | PMID 14523363 |
| 2004 | Randomised controlled trial | Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people | Bulletin of experimental biology and medicine | PMID 15452611 |
| 2004 | Clinical trial | [The use of bioregulator of the cytomedine class--epitalamin--in the treatment of combined craniocerebral trauma] | Anesteziologiia i reanimatologiia | PMID 15314861 |
| 2006 | Randomised controlled trial | Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging | Bulletin of experimental biology and medicine | PMID 17426848 |
| 1999 | Randomised controlled trial | [Long-term results of comprehensive treatment for cervical cancer with poor prognosis] | Voprosy onkologii | PMID 10532103 |
| 1979 | Clinical trial | [Action of a polypeptide epiphyseal extract on cervical cancer] | Voprosy onkologii | PMID 373241 |
| 2026 | Review / secondary | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions | Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews | PMID 41490200 |
| 2020 | Review / secondary | Peptide Regulation of Cell Differentiation | Stem cell reviews and reports | PMID 31808038 |
| 2020 | Primary study | Short Peptides Protect Oral Stem Cells from Ageing | Stem cell reviews and reports | PMID 31677028 |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-07.
Reported dosing ranges
No patient dosing protocol can be taken from the supplied records. The PubMed entries provided for this page identify study topics and populations, but they do not provide enough dose-level detail here to build a reliable dosing-range chart for self-use.
| Source | Population or context | Dose range supplied here | How to interpret it |
|---|---|---|---|
| Korkushko et al., 2011 1 | Elderly people described as rapidly aging | Not supplied in the retrieved record | The record supports that a human study existed, not a usable dosing range |
| Korkushko et al., 2006 7 | Elderly subjects with accelerated aging | Not supplied in the retrieved record | The record supports that a human study existed, not a self-use protocol |
| Korkushko et al., 2004 5 | Elderly people; melatonin-producing function | Not supplied in the retrieved record | The record supports a circadian-melatonin study question |
| Merkur'eva and Ryzhak, 2008 3 | Middle-aged and elderly women with ischemic heart disease and arterial hypertension | Not supplied in the retrieved record | The record supports a study of arterial-pressure profile, not blood-pressure treatment advice |
| Khavinson et al., 2002 2 | Retinitis pigmentosa | Not supplied in the retrieved record | The record supports a disease-specific trial question |
A clinician would need more than a peptide name to assess risk. They would review your diagnoses, medication list, pregnancy plans, cancer history, endocrine history, cardiovascular history, immune conditions, lab data when relevant, and the source and quality documentation for any product under discussion.
Legal status
| Date | Action | What it means | Source | Evidence |
|---|---|---|---|---|
| 2026-07-24 | Advisory committee reportedly voted 7-4-1 in favour of including Epitalon on the 503A bulk drug substances list | Advisory vote only, as reported. FDA has not added it to the list, and the substance is not FDA-approved. | Healio (2026-07-24) | Reported — no agency record |
| 2026-07-23 | FDA convened the Pharmacy Compounding Advisory Committee to consider seven peptide bulk drug substances for the 503A list | The meeting establishes that these substances were formally considered. It does not change any substance's status. | FDA Advisory Committee Calendar | FDA / Federal Register |
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-07. See the full legal-status tracker for every compound we follow.
Safety
Epitalon safety is not fully defined by the supplied human trial count. Human trials exist, but the records provided here do not give enough adverse-event detail to make a reassuring safety claim for healthy adults 1, 3, 5, 7.
Why a trial count does not settle safety
A substance can have randomized trials and still have important unknowns. Safety depends on study size, duration, patient selection, dose, product quality, monitoring, and whether adverse events were actively collected and reported.
The supplied Epitalon-related records include older studies and specialized groups, such as elderly participants, people with cardiovascular disease, retinitis pigmentosa, trauma, and cervical cancer contexts 2, 3, 6, 8. That makes it hard to generalize safety to a healthy person using a peptide on their own.
Product-quality risks
For peptides, source quality is a major safety issue. A vial or capsule sold online may raise risks around sterility, identity, potency, impurities, storage, and handling if it does not come through a clinician-reviewed and licensed-pharmacy process.
“Research use only” material is not made for people. If you are learning about peptide sourcing, our guide to finding a legitimate peptide source explains why a label, certificate, or website claim is not the same as medical oversight.
When to speak with a clinician
You should speak with a licensed clinician before using any peptide, especially if you are pregnant, trying to conceive, managing cancer, living with endocrine disease, living with cardiovascular disease, managing an immune condition, or taking prescription medications. The supplied Epitalon records do not answer these real-world safety questions well enough for self-directed use.
Interactions
No dedicated Epitalon interaction studies were supplied for this page. That is not proof of no interactions; it means the interaction evidence is not documented in the retrieved records.
Drug and supplement interactions
The supplied PubMed records do not provide a clear interaction table for prescription drugs, supplements, alcohol, sleep aids, hormone therapy, immune medicines, or cancer therapies. Because Epitalon is discussed in relation to pineal and cell-signaling biology, clinician review matters before combining it with other therapies 5, 10.
Condition-based cautions
Extra caution is reasonable when a person has cancer history, active cancer care, pregnancy plans, endocrine disease, cardiovascular disease, immune conditions, or complex medication use. The supplied records include cervical cancer, arterial hypertension, ischemic heart disease, and trauma contexts, but they do not turn Epitalon into a treatment recommendation for those conditions 3, 6, 8, 9.
If your goal is broader healthy-aging planning rather than a single peptide, longevity labs may be a more practical place to start. Lab trends, symptoms, medications, and risk factors often tell a clinician more than a peptide label can.
How to obtain it legally
The safe process starts with a licensed clinician, not a research-chemical vendor. Chia does not offer Epitalon, and we do not prescribe, compound, ship, or sell it.
A legitimate clinical process starts with a health history, medication review, goal review, risk review, and a decision by a licensed clinician. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
If a clinician and pharmacy are involved in any peptide discussion, the pharmacy process should be able to document identity, strength, sterility when relevant, storage, handling, and patient-specific dispensing. That is different from buying a product labeled for research use.
Questions to ask before using any peptide product
- What diagnosis, symptom, or goal is this peptide being considered for?
- What human evidence supports that specific use?
- What side effects and unknowns apply to my health history?
- What medications, supplements, or conditions could create added risk?
- Who is prescribing or supervising care?
- What pharmacy is preparing the medication, and what quality documentation exists?
- How will problems or side effects be handled?
At Chia, we do offer other clinician-reviewed peptide and longevity options, including GHK-Cu cream, NAD+, Sermorelin, and Glutathione, when clinically appropriate. These are different substances with different evidence, risks, forms, and goals; they are not substitutes for Epitalon.
| Option | Chia availability | Forms listed in Chia catalog | How it differs from Epitalon |
|---|---|---|---|
| Epitalon | Not offered by Chia | None | Education-only on this page |
| GHK-Cu | Offered by Chia | Cream, plans currently start at $159/mo | Copper peptide used in Chia’s skin-focused catalog, not an Epitalon equivalent |
| NAD+ | Offered by Chia | Injection from $179/mo; nasal spray from $119/mo | Cellular-energy focused option, not a pineal tetrapeptide |
| Sermorelin | Offered by Chia | Injection from $179/mo; nasal spray; tablets | Growth-hormone-axis peptide, not an Epitalon equivalent |
| Glutathione | Offered by Chia | Injection from $179/mo; nasal spray from $179/mo | Antioxidant-support option, not an Epitalon equivalent |
If your main question is what peptide injections are like in a supervised setting, our overview of peptide injections explains the basics of route, monitoring, storage, and expectations.
Frequently asked questions
Epithalon, also called Epitalon, is studied as a synthetic pineal tetrapeptide. Human studies exist in specific areas like accelerated aging, circadian melatonin rhythm, arterial-pressure profile, retinitis pigmentosa, trauma, and cervical cancer contexts. Those studies do not prove broad anti-aging benefit for healthy adults.
The supplied human records do not prove that Epitalon makes people look younger. Some mechanistic literature discusses aging biology, cell differentiation, and telomerase-related hypotheses, but that is not the same as a proven cosmetic or appearance outcome.
The supplied records do not establish Epitalon as a cause of weight gain or weight loss. If weight changes happen while using any peptide, a clinician should review diet, medications, hormones, fluid status, and other health factors.
It depends on what you mean by “work.” Epithalon has PubMed-indexed human studies, including randomized trials, so the evidence base is not empty. But the supplied records are narrow and do not prove broad longevity, lifespan, cosmetic, or weight benefits for healthy adults.
They are closely related names in the older pineal-peptide literature, but they should not be treated as automatically interchangeable products. Epitalon is commonly described as the synthetic tetrapeptide AEDG, while Epithalamin or epithalamine appears in older studies of pineal peptide preparations.
This page does not provide a standard dose. The supplied PubMed records do not give enough dosing detail here to create a patient dosing range, and published-study dosing should not be used as a self-use protocol.
No. Chia does not offer Epitalon, and we do not prescribe, compound, ship, or sell it. Chia does offer other clinician-reviewed peptide and longevity treatments when clinically appropriate, but those are different substances and not Epitalon substitutes.
Avoid treating research-chemical vendors as a substitute for medical care. A legitimate medication process involves clinician evaluation, prescription oversight when appropriate, and a licensed pharmacy process with quality documentation.
References
- 1.PMID 22451889 [randomised controlled trial] Korkushko OV, Khavinson VKh, Shatilo VB, et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of experimental biology and medicine. 2011.
- 2.PMID 12195242 [clinical trial] Khavinson V, Razumovsky M, Trofimova S, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro endocrinology letters. 2002.
- 3.PMID 18546838 [randomised controlled trial] Merkur'eva GA, Ryzhak GA. [Effect of the pineal gland peptide preparation on the diurnal profile of arterial pressure in middle-aged and elderly women with ischemic heart disease and arterial hypertension]. Advances in gerontology = Uspekhi gerontologii. 2008.
- 4.PMID 14523363 [randomised controlled trial] Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro endocrinology letters. 2003.
- 5.PMID 15452611 [randomised controlled trial] Korkushko OV, Khavinson VKh, Shatilo VB, et al. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bulletin of experimental biology and medicine. 2004.
- 6.PMID 15314861 [clinical trial] Lebedeva EA, Zavarzina PZh, Nemkova ZA. [The use of bioregulator of the cytomedine class--epitalamin--in the treatment of combined craniocerebral trauma]. Anesteziologiia i reanimatologiia. 2004.
- 7.PMID 17426848 [randomised controlled trial] Korkushko OV, Khavinson VKh, Shatilo VB, et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of experimental biology and medicine. 2006.
- 8.PMID 10532103 [randomised controlled trial] Vishnevskaia EE, Kosenko IA. [Long-term results of comprehensive treatment for cervical cancer with poor prognosis]. Voprosy onkologii. 1999.
- 9.PMID 373241 [clinical trial] Dekster LI, Il'in NV, Azarova MA, et al. [Action of a polypeptide epiphyseal extract on cervical cancer]. Voprosy onkologii. 1979.
- 10.PMID 31808038 [review/secondary] Khavinson V, Linkova N, Diatlova A, et al. Peptide Regulation of Cell Differentiation. Stem cell reviews and reports. 2020.
- 11.PMID 41490200 [review/secondary] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026.
- 12.PMID 40141333 [review/secondary] Araj SK, Brzezik J, Mądra-Gackowska K, et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences. 2025.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
